A Study of LAD191 in Adults With Hidradenitis Suppurativa
Recruiting · Phase 2 · NCT07151937
Conditions: Hidradenitis Suppurativa
At a glance
- Research payments reported, 2025
- $106,423
- U.S. investigators named
- 4
- Sites paid
- 3
- Planned or actual enrollment
- 200
About the trial
- Sponsor
- Almirall, S.A.
- Tested
- LAD191 (drug), Placebo (other), Adalimumab (drug)
- Dates
- Started 2025-11-05; completion 2027-11-25
- Results posted
- Not yet
The main purpose of this study is to assess the efficacy of multiple dosing regimens of LAD191 compared to placebo in participants with moderate-to-severe Hidradenitis Suppurativa (HS) and to access the safety, tolerability, pharmacokinetic and immunogenicity in participants with moderate-to-severe HS.
From ClinicalTrials.gov, last updated 2026-05-11. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Almirall LLC reported $106,423 in research payments for this study in 2025 (11 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Artis P. Truett III, M.D. Dermatology · Owensboro, KY
- Tarannum Jaleel Dermatology · Boston, MA
- Joel Schlessinger, M.D Dermatology · Omaha, NE
- Maira Fonseca Dermatology · Bronx, NY
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Equity Medical LLC $69,600
- Duke University $20,000
- Skin Specialists PC dba Schlessinger MD $16,823
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.